Merck predicts flat earnings for 2015

Net income down amid switch away from pharma

Hikma set to join pharma blue-chips

Jordanian drugmaker outgrows Mideast roots

Unnerving history of the head transplant

Moral concerns are as great a barrier as surgical problems, writes Anjana Ahuja

GSK-Novartis deal ‘a model’ for industry

Pharma groups bet heavy on ‘precision M&A’

UK drug manufacture drops by a quarter

Blow to coalition ambition to promote high-growth industry

Tullow faces blue-chip relegation

Hikma Pharma ready to grab spot in the top tier

Chi-Med poised for China drug milestone

Cancer treatments set to be filed for regulatory approval in 2016

Outlook improves for European companies

Deflation a concern while ability to push up prices ‘limited’


Nikon buys Optos for £259m

Japanese group diversifying into medical technology

Medicine Chemistry, AstraZeneca R&D Charnwood, UK

AstraZeneca carves out antibiotic research

Standalone company to develop new drugs pipeline

GSK chief’s pay halved after China scandal

Witty pays price for falling sales and corruption woes

Sanofi sets pricing strategy for new drug

Pharma group’s Toujeo insulin wins FDA approval

US and Asian groups grab European patents

Majority of filings come from companies outside the continent

Pharmacyclics considers $19bn sale

Johnson & Johnson explores acquisition of US cancer drugs maker

Hospira and Celltrion launch biosimilars

Cut-price versions of blockbuster anti-inflammatory go on sale

UK allows three-parent babies

First country to approve mitochondrial replacement IVF procedure

Eli Lilly stays out of deals fray

Drugmaker bets on success of ‘moon shot’ drugs

Valeant shares surge 13% on Salix deal

Pharma group’s debt to soar after it raises $22bn in new finance

Valeant/Salix: at what cost

Proposed cuts at the latest target amount to most of its budget

Valeant agrees to buy Salix for $14.5bn

Deal marks return to big-ticket M&A after the defeat of Allergan bid last year


More FT Twitter accounts